EPIX - Biotech Pre-earnings Run LONGEPIX on the 15-minute chart shows a solid trend up with a set of moving averages as the
guardrails now in a bit of a pullback. The after-hours price action will not appear on the chart
but price jumped 5%. Earnings are anticipated for 2/8 or 2/9 as best as I can tell. Internet
search information is not consistent. So, if tomorrow this is still pre-earnings but price popped
5% overnight, I will take a small long position. If the price is still pulled back to the slowest
moving average, I will take a larger position. No matter I will assess it on a 3-5 minute time
frame and recheck internet information regarding an earnings report. One news catalyst is that
Secretary of Defense has been in and out of the hospital ( DC VAMC) with prostate cancer
and maybe currently getting treatment in a clinical trial of an EPIX drug per the NIH
in Bethesda. Biotech is forecasted to be one of the hottest sectors for 2024. EPIX has
a trend up that impresses me. I will go long on this when I find a best entry and possibly in the
next trading session. The options chain is minimal volume as so represents a liquidity trap.
I will not go there.
EPIX trade ideas
EPIX: Bullish FlagBullish Flag
Pros:
Descending volume during formation
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 9
250RSI above 50
200MA ascending
Cons:
Gap may want to get filled
Target:
PT = 52.04$
Thank you to those who donate Coins!
Stay Humble, have fun, make money!
EPIX Big Push Forward - 86% Up IN ONE MONTHESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
SHORT INTEREST
102.77K 08/15/19
P/E Current
-1.08
P/E Ratio (with extraordinary items)
-1.45
Average Recommendation: BUY
Average Target Price: 18.63
Newbie. A friend's recommended EPIX. Anyone familiar with it?Everything I read about Essa Pharma (NASDAQ: EPIX) sounds positive. They claim to have a game-changing prostate cancer technology and significant news ahead. But it is very difficult to buys shares because the 1M float seems tightly held. Four institutions (BVF, Clarus, Omega, Eventide) own 90% of common paid well over $12 for their shares, an analyst has a $24/share price target, and it's funded to 2020. Please help me understand its technical setup because fundamentals seem strong but I don't know much about technical analysis. Thank you!